Articles from Teiko

Teiko, a CLIA clinical laboratory for monitoring the immune response, announced the publication of a review paper in Bioanalysis: https://doi.org/10.1080/17576180.2026.2744519. The paper, "Application of sample stabilization and mass cytometry in global oncology trials: lessons from regulatory T cell monitoring," draws on the companies' work in the first-in-human study of roginolisib, clinical precision oncology company iOnctura's conformation-selective PI3K-delta inhibitor that locks the enzyme in its inactive state, and describes Teiko's mass cytometry work in three ongoing roginolisib trials.

Teiko, a CLIA clinical laboratory focused on monitoring the immune response, today announced that the Company will present four posters at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting.

Teiko is pleased to announce a collaboration with the University of Utah’s U of U Health and the Huntsman Cancer Institute to develop a series of breakthrough immune profiling tests, starting with Acute Myeloid Leukemia (AML). This first study marks the start of a broader, long-term collaboration between the two organizations, with plans to extend the work across multiple disease areas where stabilized samples and high-resolution immune profiling make a difference for patients. As part of this initiative, University of Utah Health Innovations will become an investor in Teiko.